Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Published:2014-11 Issue:6 Volume:15 Page:418-425
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Pujol Jean-Louis,Paz-Ares Luis,de Marinis Filippo,Dediu Mircea,Thomas Michael,Bidoli Paolo,Corral Jesus,San Antonio Belen,Chouaki Nadia,John William,Zimmermann Annamaria,Visseren-Grul Carla,Gridelli Cesare

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference21 articles.

1. 2011 Focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non–small-cell lung cancer;Azzoli;J Clin Oncol,2011

2. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Peters;Ann Oncol,2012

3. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer;Mubarak;BMC Cancer,2012

4. Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea;Gerber;J Clin Oncol,2013

5. Importance of quality of life in patients with non–small-cell lung cancer;Camps;Clin Lung Cancer,2009

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms;Pneumologie;2023-10

2. Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience;Lung Cancer;2022-03

3. The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer;Clinical Pharmacology & Therapeutics;2022-02-21

4. Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non–Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies;Clinical Lung Cancer;2021-10

5. Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer;Medicine;2021-05-07